36氪获悉，辉瑞制药宣布，HYMPAVZI™（马塔西单抗/marstacimab-hncq）近日获美国食品药品监督管理局（FDA）批准，用于规律性治疗不伴凝血因子抑制物的血友病A（先天性凝血VIII因子缺乏症）或血友病B（先天性凝血IX因子缺乏症）的 ...

10月15日，辉瑞制药宣布，HYMPAVZI ...

10月15日，辉瑞官微发布消息称，期创新药物HYMPAVZI™（马塔西单抗/marstacimab-hncq）获美国食品药品监督管理局（FDA）批准，用于规律性治疗不伴凝血因子抑制物的血友病A（先天性凝血VIII因子缺乏症）或血友病 ...

当地时间10月14日，在收购新加坡英康保险多数股权的拟议交易被叫停后，德国保险公司安联表示，将考虑修改收购交易的结构。安联称：“我们深信，与英康保险——一家与安联拥有相同价值观并致力于为客户提供卓越服务的保险公司的合作，将使新加坡客户和社会受益。”在 ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...